stoxline Quote Chart Rank Option Currency Glossary
Jasper Therapeutics, Inc. (JSPR)
23.92  0.1 (0.42%)    05-24 16:00
Open: 23.8
High: 24.3256
Volume: 143,685
Pre. Close: 23.82
Low: 23.1864
Market Cap: 361(M)
Technical analysis
2024-05-27 4:46:59 PM
Short term     
Mid term     
Targets 6-month :  30.57 1-year :  35.71
Resists First :  26.18 Second :  30.57
Pivot price 22.41
Supports First :  22.45 Second :  20.14
MAs MA(5) :  23.57 MA(20) :  22.72
MA(100) :  20.41 MA(250) :  14.32
MACD MACD :  -0.2 Signal :  -0.5
%K %D K(14,3) :  58.3 D(3) :  53.8
RSI RSI(14): 54.7
52-week High :  31.01 Low :  4
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ JSPR ] has closed below upper band by 14.9%. Bollinger Bands are 39.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 24.35 - 24.47 24.47 - 24.57
Low: 22.91 - 23.04 23.04 - 23.16
Close: 23.72 - 23.93 23.93 - 24.11
Company Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Headline News

Tue, 21 May 2024
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.29 Consensus Target Price from Analysts - MarketBeat

Thu, 16 May 2024
Jasper Therapeutics, Inc. (NASDAQ:JSPR) to Post Q2 2024 Earnings of ($0.96) Per Share, William Blair Forecasts - Defense World

Mon, 13 May 2024
Jasper Therapeutics Announces Briquilimab Development Program in Asthma - GlobeNewswire

Sat, 11 May 2024
Jasper Therapeutics (JSPR) Stock Forecast and Price Target 2024 - MarketBeat

Thu, 09 May 2024
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Forecasted to Post Q1 2024 Earnings of ($1.43) Per Share - Defense World

Thu, 09 May 2024
Institutions along with retail investors who hold considerable shares inJasper Therapeutics, Inc. (NASDAQ:JSPR) come under pressure; lose 12% of holdings value - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 15 (M)
Shares Float 9 (M)
Held by Insiders 4.9 (%)
Held by Institutions 62.6 (%)
Shares Short 614 (K)
Shares Short P.Month 452 (K)
Stock Financials
EPS -61.8
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.03
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -60.1 %
Return on Equity (ttm) -112.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.49
Qtrly Earnings Growth 0 %
Operating Cash Flow -52 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -0.39
PEG Ratio 0
Price to Book value 3.4
Price to Sales 0
Price to Cash Flow -6.94
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android